Bladder cancer drug combo trial halted early – what we know
NCT ID NCT04586244
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tested several drug combinations (retifanlimab, epacadostat, INCAGN02385, INCAGN02390) given before bladder removal surgery in 30 patients with muscle-invasive bladder cancer who could not take the standard chemo drug cisplatin. The trial was terminated early, so the planned analysis of immune cell changes in the tumor could not be fully completed. The main goal was to see if these drugs could boost the body's immune response against the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- retifanlimab, epacadostat, INCAGN02385, INCAGN02390
- What this could lead to
- If successful, this could point toward effective neoadjuvant treatments for bladder cancer patients who cannot use standard chemotherapy.
- What could go wrong
- The trial was terminated early with limited data, so results are inconclusive. The combinations may not improve outcomes and could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCLE-INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Azienda Ospedaliera Universitaria Integrata Verona (Ospedale Borgo Roma)
Verona, 37124, Italy
-
Hopital Europeen Georges Pompidou (Hegp)
Paris, 75015, France
-
Hospital Saint Louis
Paris, 75475, France
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele
Milan, 20132, Italy
-
Istituto Tumori Giovanni Paolo Ii Irccs Ospedale Oncologico Bari
Bari, 70124, Italy
-
L Azienda Ospedaliero-Universitaria Di Bologna Policlinico S. Orsola - Malpighi
Bologna, 40138, Italy
-
Ohio State University Medical Center Division of H
Columbus, Ohio, 43210, United States
-
Oregon Health & Science University
Portland, Oregon, 97239-4501, United States
-
Universita Campus Bio Medico Di Roma
Roma, 00128, Italy
-
University of Cincinnati
Cincinnati, Ohio, 45267, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can a Two-Drug attack shrink Hard-to-Treat bladder tumors?
- Bladder cancer breakthrough? new combo aims to save the bladder
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- New biologic drug DBC-664 takes aim at Hard-to-Treat cancers